Canon Stroke and Vascular Research Center

What Canon Stroke and Vascular Research Center does

The Canon Stroke and Vascular Research Center (CSVRC) is a private academic research center founded in 1991 and co-located on the 8th floor of the Clinical Translational Research Center above the Gates Vascular Institute in Buffalo, New York. It is affiliated with the University at Buffalo's Jacobs School of Medicine and Biomedical Sciences and operates with a small team of 11–50 staff, faculty, and laboratory technicians. Its mission is the research, diagnosis, and treatment of stroke and vascular disease through minimally invasive image-guided interventions, advanced imaging modalities, and computational analysis of hemodynamics.

CSVRC's technology portfolio spans high-speed 1000 fps angiography, micro-angiographic fluoroscopy (MAF), an FDA-cleared Dose Tracking System (DTS) licensed to Canon Medical Systems for worldwide distribution, patient-specific 3D-printed vascular phantoms, computational fluid dynamics modeling for aneurysm rupture prediction, and image-based biomarkers developed in conjunction with its AI spinoff QAS.AI. The center functions as a multidisciplinary hub combining neurosurgery, radiation physics, biomedical engineering, and radiology under the same roof as a high-volume clinical site, enabling rapid bench-to-bedside translation.

CSVRC is funded primarily through federal research grants (NIH, NSF) and a long-standing corporate partnership with Canon (formerly Toshiba), which has contributed roughly $25.8 million cumulatively over 13 years. Its commercial revenue model is indirect: technology is monetized through licensing agreements (DTS to Canon Medical Systems) and spinout companies (QAS.AI for AI surgical assistance, Neurovascular Diagnostics for a blood-based aneurysm screening test), with additional support from tax-deductible donations to its Stroke Research Fund.

Name

Canon Stroke and Vascular Research Center

Legal name

Canon Stroke and Vascular Research Center

Website

https://csvrc.com

Company type

Private

Founded year

1991

Operating status

Operating

Headcount range

11–50 employees

Short description

Canon Stroke and Vascular Research Center is a University at Buffalo-affiliated academic research center developing advanced imaging, AI, and device technologies for minimally invasive stroke and aneurysm treatment, funded by NIH/NSF grants and a Canon Medical Systems licensing partnership.

Ownership category

akta.pro rank

Product category

Medical Imaging and Neurovascular Research

NAICS

Scientific Research and Development Services (5417), Surgical and Medical Instrument Manufacturing (339112)

SIC

Surgical & Medical Instruments & Apparatus (3841), Industrial Instruments For Measurement, Display, And Control (3823)

akta.pro primary industry

Thrombectomy, Embolic Protection & Stroke Intervention Devices (HLAHAFAJ)

akta.pro secondary industries

Stroke & Vascular Neurology (HLAKAIAG), Peripheral Vascular Intervention (PAD Stents, Balloons, Atherectomy) (HLAHAFAE), Vascular Access & Closure Devices (Sheaths, Guidewires, Closure Systems) (HLAHAFAK)

Keywords

• Medical imaging research
• Neurovascular device development
• Stroke treatment research
• Biomedical engineering
• Endovascular imaging

Headquarters

HQ city

Buffalo

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure

Revenue model

1. Research Grants: Primary funding from federal agencies including NIH, NSF, NINDS, NHLBI, NIBIB for stroke and vascular research projects. NIH R01 grants support high-speed angiography development.
2. Technology Licensing: Licensing of developed technologies to industry partners. Dose Tracking System licensed to Canon Medical Systems with worldwide distribution.
3. Donations: Tax-deductible donations to Stroke Research Fund supporting computing systems, laboratory supplies, specimen collection, and personnel.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Core offering

Canon Stroke and Vascular Research Center is a multidisciplinary academic research center that develops imaging technologies, endovascular devices, and AI-based surgical decision support tools for the diagnosis and treatment of stroke and vascular disease. Its commercial outputs include the FDA-cleared Dose Tracking System (licensed to Canon Medical Systems), the QAS.AI real-time surgical assistance platform, 1000 fps high-speed angiography, 3D-printed patient-specific vascular phantoms, and the Asymmetric Flow Diverter device.

Product overview

The Canon Stroke and Vascular Research Center (CSVRC) operates as a multidisciplinary research center focused on stroke and vascular disease diagnosis and treatment through minimally invasive image-guided interventions, advanced imaging modalities, and computational analysis. The core portfolio includes the QAS.AI AI-powered surgical decision support platform for real-time complication detection and outcome prediction; the 1000 fps High-Speed Angiography system for unprecedented blood flow visualization; the FDA-cleared Dose Tracking System licensed to Canon Medical Systems; patient-specific 3D-printed vascular phantoms for surgical planning; and Computational Fluid Dynamics modeling for aneurysm rupture risk assessment. These products work together as an integrated ecosystem enabling pre-surgical planning, intraoperative guidance, and post-procedural outcome prediction for neurovascular interventions.

Differentiator

Problem solved

Functional benefit

Products and services

• QAS.AI (Quantitative Angiographic Systems) AI-powered real-time surgical decision support system that detects complications during aneurysm surgery, forecasts treatment success, and predicts aneurysm healing probability at one-year post-procedure; integrates with angiographic systems regardless of manufacturer. For neurosurgeons and interventional radiologists.
• Dose Tracking System (DTS) FDA-cleared real-time radiation dose tracking system providing color-coded skin dose mapping during fluoroscopic procedures. Licensed to Canon Medical Systems with worldwide distribution. For interventional radiology departments and hospitals.
• 1000 fps High-Speed Angiography High-speed angiography imaging system operating at 1000 frames per second to visualize intricate details of blood flow during interventional procedures. For clinical researchers and interventional neuroradiology departments.
• 3D-Printed Vascular Phantoms Patient-specific 3D-printed arterial geometries used for benchtop device testing and pre-surgical planning. Includes Circle of Willis, aneurysm, cardiac, and aortic arch models. For neurosurgeons, medical device companies, and biomedical researchers.
• Micro-Angiographic Fluoroscopy (MAF) Region-of-interest high-resolution X-ray imaging detector system for improved image guidance during neurovascular interventions, providing superior real-time image quality far exceeding conventional imagers. For neurovascular intervention suites and hospitals.
• Asymmetric Flow Diverter (AFD) Asymmetric flow diverter device designed for bifurcation aneurysm treatment, with low-porosity region covering the aneurysm neck while maintaining high porosity for adjacent arteries. For neurovascular device manufacturers and interventional neuroradiologists.

Quantifiable outcome

• Dose Tracking System received Minnie Award as Best New Radiology Software 2014 and Most Innovative Technology at 2012 RSNA meeting
• +3 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability9 records

Feature8 records

Partnerships

Six partnerships are on record, tiered core and secondary.

• Canon Medical SystemscoreOEM/ Whitelabel/ Licensing PartnerDose Tracking System licensed to Canon Medical Systems for worldwide distribution. Ongoing collaboration for development and implementation of imaging technologies including high-resolution detectors and dose reduction systems.
• Kaleida Health System / Gates Vascular InstitutecoreStrategic or Co-development PartnerCSVRC co-located above GVI since 2012, enabling direct collaboration between physicians and scientists. UB neurosurgeons conduct procedures at GVI while using CSVRC's research facilities for device testing and optimization.
• Jacobs InstitutecoreStrategic or Co-development PartnerNonprofit organization dedicated to accelerating development of next-generation vascular medicine technologies. Located upstairs from GVI/CTRC building. Provides real-time feedback from surgical cases to device companies for device improvement.
• University at Buffalo Jacobs School of Medicine and Biomedical SciencescoreStrategic or Co-development PartnerAffiliated academic institution providing faculty, students, and research infrastructure. Multidisciplinary team includes investigators from Neurosurgery, Radiology, Biomedical Engineering, and various other departments.
• University of South FloridasecondaryStrategic or Co-development PartnerClinical evaluation site for QAS.AI AI surgical assistance technology, specifically the Department of Neurosurgery and Brain Repair.
• Mercy Hospital of BuffalosecondaryStrategic or Co-development PartnerClinical evaluation site for QAS.AI AI surgical assistance technology alongside Gates Vascular Institute.

Scale indicators7 records

Recent moves9 records

Expansion highlights5 records

Direct peers

• RapidAI: RapidAI provides AI-based imaging analysis for stroke and other neurovascular conditions, directly competing with CSVRC's QAS.AI spinoff in the AI-assisted stroke decision support space. Both serve hospital stroke centers with image analysis and clinical decision support tools.
• Viz.ai: Viz.ai is a direct competitor to QAS.AI in AI-powered clinical decision support for stroke and neurovascular care. Both companies apply computer vision and AI to imaging data to accelerate diagnosis and treatment decisions, and both target similar clinical customers (stroke centers, neurointerventional radiologists).
• Penumbra: Penumbra is a leading manufacturer of thrombectomy and neurovascular devices, with overlapping technology and clinical focus with CSVRC's stroke intervention and device development programs. Both companies are active in the venous and arterial thrombectomy space.

Others

• Canon Medical Systems: Canon Medical Systems is CSVRC's primary industry partner and worldwide distributor of the Dose Tracking System. As a major medical imaging OEM, Canon provides the commercial pathway for licensed CSVRC technologies, making it a critical enabler rather than direct competitor.

Broad incumbents

• Siemens Healthineers: Siemens Healthineers is a major medical imaging equipment manufacturer with overlap in angiography and fluoroscopy markets where CSVRC's high-speed angiography and MAF technologies compete. As a broad incumbent, Siemens has substantially greater resources for productization.
• Philips (Image-Guided Therapy): Philips develops interventional imaging systems and related software for neurovascular procedures, overlapping with CSVRC's image-guided intervention research. As a large incumbent, Philips has substantial product development and global distribution capabilities.
• Stryker (Neurovascular): Stryker's Neurovascular division offers a broad portfolio of stroke intervention devices, flow diverters, and access products that overlap with CSVRC's asymmetric flow diverter and stroke intervention device research. As a large incumbent, Stryker has substantially greater commercialization resources.
• Medtronic (Neurovascular): Medtronic's Neurovascular business develops flow diversion, thrombectomy, and other stroke intervention products overlapping with CSVRC's research areas. As a diversified medtech incumbent, Medtronic has far greater R&D and commercial scale.

Emerging players

• Aidoc: Aidoc is an AI radiology company that applies deep learning to medical imaging, with overlap in the image-based clinical decision support space that QAS.AI addresses. Both serve radiologists and emergency medicine workflows with AI-augmented image analysis.
• Imperative Care: Imperative Care develops stroke thrombectomy and vascular access technologies, with overlapping device categories and clinical applications to CSVRC's research programs. Both target the ischemic stroke intervention market.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/canon-stroke-and-vascular-research-center

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Canon Stroke and Vascular Research Center